ArticleeLife2020
Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- HAMMER: hairpin-based APOBEC3A-mediated mRNA editing reporter.Nucleic acids research · 2026Article
- APOBEC3B regulates HPV replication by inducing R-loop formation and DNA damage.PLoS pathogens · 2026Article
- HAMMER: Hairpin-based APOBEC3A-mediated mRNA editing reporter.bioRxiv : the preprint server for biology · 2026Article
- E2F transcription factors as multimodal biomarkers for pan-cancer management.Scientific reports · 2025Article
- Mechanism of DNA replication fork breakage and PARP1 hyperactivation during replication catastrophe.Science advances · 2025Article
- Transcriptome-based network analysis of cell cycle-related genes in response to blue and red light in maize.AoB PLANTS · 2023Article
- Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer.PLoS genetics · 2023Article
- Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases.Cell reports. Medicine · 2023Article
- Mitochondrial double-stranded RNA triggers induction of the antiviral DNA deaminase APOBEC3A and nuclear DNA damage.The Journal of biological chemistry · 2023Article
- Clinical Implications of APOBEC3-Mediated Mutagenesis in Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Review
- Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase.Cells · 2023Article
- Primary mucosal melanomas of the head and neck are characterised by overexpression of the DNA mutating enzyme APOBEC3B.Histopathology · 2023Article
- APOBEC3: Friend or Foe in Human Papillomavirus Infection and Oncogenesis?Annual review of virology · 2022Review
- Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer.Nature communications · 2022Article
- Soma-to-germline transformation in chromatin-linked neurodevelopmental disorders?The FEBS journal · 2022Review
- ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells.Scientific reports · 2022Article
- The von Hippel-Lindau Cullin-RING E3 ubiquitin ligase regulates APOBEC3 cytidine deaminases.Translational research : the journal of laboratory and clinical medicine · 2021Article
- Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.Cancer discovery · 2021Article
- Infection of Bronchial Epithelial Cells by the Human Adenoviruses A12, B3, and C2 Differently Regulates the Innate Antiviral Effector APOBEC3B.Journal of virology · 2021Article
- Foamy Viruses, Bet, and APOBEC3 Restriction.Viruses · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 4 countries.
Pieter A RoelofsDepartment of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, Center for Genome Engineering, University of Minnesota, Minneapolis, United States.ORCID 0000-0002-4921-7089
Chai Yeen Goh *Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Boon Haow Chua *Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Matthew C JarvisDepartment of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, Center for Genome Engineering, University of Minnesota, Minneapolis, United States.
Teneale A StewartDepartment of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, Center for Genome Engineering, University of Minnesota, Minneapolis, United States.ORCID 0000-0003-4837-9315
Jennifer L McCannDepartment of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, Center for Genome Engineering, University of Minnesota, Minneapolis, United States.ORCID 0000-0003-0458-1335
Rebecca M McDougleDepartment of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, Center for Genome Engineering, University of Minnesota, Minneapolis, United States.
Michael A CarpenterDepartment of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, Center for Genome Engineering, University of Minnesota, Minneapolis, United States.
John Wm MartensErasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.ORCID 0000-0002-3428-3366
Paul N SpanDepartment of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-1930-6638
Dennis KappeiCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-3582-2253
Reuben S HarrisDepartment of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, Center for Genome Engineering, University of Minnesota, Minneapolis, United States.ORCID 0000-0002-9034-9112
University of Minnesota · USNational University of Singapore · SGErasmus MC · NLRadboud University Nijmegen · NL
Funding
PROJECT 3 – BIOLOGY OF DNA DEAMINASES IN CANCERP01CA234228 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Reuben S Harris · 2019 to 2026
$14.5MThe APOBEC in APOBEC mutagenesisF31CA243306 · NCI · UNIVERSITY OF MINNESOTA · PI JARVIS, MATTHEW C · 2019 to 2021
$94kKWF Kankerbestrijding KWF10270National Research Foundation Singapore NMRC/OFYIRG/055/2017NCI NIH HHS F31 CA243306NCI NIH HHS P01 CA234228
Abstract
APOBEC3B (A3B)-catalyzed DNA cytosine deamination contributes to the overall mutational landscape in breast cancer. Molecular mechanisms responsible for
Indexed as
Signal TransductionCytidine DeaminaseE2F Transcription FactorsHEK293 CellsHumansMCF-7 CellsMinor Histocompatibility AntigensProtein BindingAPOBEC3B protein, humanCytidine DeaminaseE2F Transcription FactorsMinor Histocompatibility AntigensAPOBEC3Bcancer biologycancer mutagenesischromosomesDREAM complexgene expressionhumanPRC1.6 complexRB/E2F pathwaytranscriptional regulation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.